Economic evaluation of hematopoietic stem cell transplantation

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Barr, Ronald D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Economic; Evaluation; Stem cell; Transplantation

Indexed keywords

IMATINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; COMPARATIVE EFFECTIVENESS; DEVELOPING COUNTRY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84859786424     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169157176     Document Type: Article

References (28)

1. Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1987.
2. Barr R, Furlong W, Henwood J, Feeny D, Wegener J, Walker I, et al. Economic evaluation of allogeneic bone marrow transplantation: A rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol. 1996;14:1413-20.
3. Stranges E, Russo CA, Friedman B. Procedures with the most rapidly increasing hospital costs, 2004-2007. HCUP statistical brief #82. December 2009. Agency for Healthcare Research and Quality, Rockville, MD, USA. http://www.hcup-us.ahrq-gov/ reports/statbriefs/sb82.pdf
4. Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, et al. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukemia: a systematic review. Health Technol Assess. 2010;14(54):iii-iv, ix-xi, 1-141.
5. Lin Y-F, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, et al. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010;16:1272-81.
6. Madero L, Gonzalez VM, Ramirez M, Quintero V, Benito A, Diaz MA. Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplant. 2000;26:269-73.
7. Vellenga E, Agthoven M, Croockewit LF, Verdonck LF, Wijermans PJ, van Oers MH, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol. 2001;114:319-26.
8. Howard DH, Meltzer D, Kollman C, Maiers M, Logan B, Gragert L, et al. Use of cost effectiveness analysis to determine inventory size for national cord blood bank. Med Decis Making. 2008;28:243-53.
9. Van Agthoven M, Groot MT, Verdonck LF, Lowenberg B, Schattenberg AV, Oudshoorn M, et al. Cost analysis of HLAidentical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukemia or acute lymphoblastic leukemia. Bone Marrow Transplant. 2002;30:243-51.
10. Chen X-H, Zhang C, Zhang X, Gao L, Gao L, Kong P-Y, et al. Cost and outcome in stem cell collections in HLA haploidentical mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilized blood and bone marrow for patients with hematologic malignancies. Transfus Apher Sci. 2010;43:23-8.
11. Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM, et al. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 2003;31:205-10.
12. Svahn B-M, Ramberger M, Alvin O, Karlsson H, Ringden O. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant. 2011 [29 Aug; Epub ahead of print].
13. Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ, et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007;40:209-17.
14. Cordonnier C, Maury S, Esperou H, Pautas C, Beaune J, Rodet M, et al. Do mini transplants have mini costs? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant. 2005;36:649-54.
15. Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005;25:325-34.
16. Krecji M, Mayer J, Doubek M, Brychtova Y, Pospisil Z, Racil Z, et al. Clinical outcomes and direct hospital costs of reducedintensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant. 2006;38:483-91.
17. De Lissovoy G, Hurd D, Carter S, Beatty B, Ewell M, Henslee-Downey J, et al. Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T cell depletion vs. unmanipulated grafts for the prevention of graft-versus-host disease. Bone Marrow Transplant. 2005;36:539-46.
18. Gratwohl A, Passweg J, Baldomero H, Horisberger B, Urbano-Ispizua A. Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol. 2002;117:451-68.
19. Ruiz-Arguelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. Int J Hematol. 2002;76 Suppl 1:376-9.
20. Gomez-Almaguer D. The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol. 2002;27 Suppl 1:380-82.
21. Ngamkiatphaisan S, Sriratanaban J, Kamoiratanakul P, Intraqumtomchai T, Noppakun N, Jonqudomsuk P. Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 2007;90:2565-73.
22. El-Zimaity MM, Hassan EA, Abd El-Wahab SE, Abd El-Ghaffar AA, Mahmoud NA, Elafifi AM, et al. Stem cell transplantation in hematological disorders. A developing country experience-impact of cost considerations. Saudi Med J. 2008;29:1484-9.
23. Mishra V, Vaaler S, Brinch L. A prospective cost evaluation related to allogeneic haematopoietic transplantation including pretransplant procedures, transplantation and 1 year follow-up procedures. Bone Marrow Transplant. 2001;28:1111-6.
24. Orsi C, Bartolozzi B, Messori A, Bosi A. Event-free survival and cost-effectiveness in adult acute lymphoblastic leukemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant. 2007;40:643-9.
25. Clarke SA, Skinner R, Guest J, Darbyshire P, Cooper J, Vora A, et al. Clinical outcomes and health-related quality of life (HRQOL) following haemopoietic stem cell transplantation (HSCT) for paediatric leukaemia. Child Care Health Dev. 2011;37:571-80.
26. Watson M, Buck G, Wheatley K, Homewood JR, Goldstone AH, Rees JK, et al. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML10 Trial. Eur J Cancer. 2004;40:971-6.
27. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20:332-42.
28. Vigdor ER. Coverage does matter: the value of health foregone by the uninsured. In: Hidden costs, value lost: uninsurance in America. Washington (DC): National Academy Press; 2003. p. 129-69.